| Bioactivity | Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy[1]. |
| CAS | 2644673-01-6 |
| Formula | C23H23F2N7 |
| Molar Mass | 435.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu X, et al. Cyy-272, an indazole derivative, effectively mitigates obese cardiomyopathy as a JNK inhibitor. Biomed Pharmacother. 2024 Sep;178:117172. |